Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome
Variant / mechanism
COL4A4
Readthrough of COL4A4 premature termination codons by exaluren (formerly ELX-02), a eukaryotic ribosome-targeted glycoside
Summary
Nonsense variants in Alport syndrome, in autosomal recessive forms and in hemizygous X-linked disease, introduce premature termination codons and carry a poor prognosis, with kidney failure typically by early adulthood. Exaluren (formerly ELX-02), a eukaryotic ribosome-targeted glycoside preferentially taken up by kidney cells, promotes readthrough of premature but not native termination codons. In this proof-of-mechanism study, three patients aged 12 to 18 years with autosomal recessive Alport syndrome and a COL4A4 premature termination codon received daily subcutaneous exaluren (0.75 mg/kg) for 8 weeks, with no new safety signals. Kidney biopsies before and after treatment showed increased collagen α3(IV), α4(IV) and α5(IV) abundance, physiologically localised α5(IV) and partially improved podocyte morphology in all three participants. Proteinuria changes were inconsistent and hematuria persisted in all.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
According to the authors, this is the first human evidence of collagen IV readthrough, and it gives practical weight to the nonsense versus missense distinction in an Alport variant report. But three patients, eight weeks and a safety primary endpoint say nothing about the effect on kidney function: hematuria persists and proteinuria does not change consistently. To be confirmed in longer trials, which the authors consider justified.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 1/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 5/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime